425 related articles for article (PubMed ID: 26624971)
1. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
[TBL] [Abstract][Full Text] [Related]
3. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
4. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
6. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Esserman LJ; Berry DA; DeMichele A; Carey L; Davis SE; Buxton M; Hudis C; Gray JW; Perou C; Yau C; Livasy C; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; van 't Veer L; Hylton N
J Clin Oncol; 2012 Sep; 30(26):3242-9. PubMed ID: 22649152
[TBL] [Abstract][Full Text] [Related]
8. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Esserman LJ; Berry DA; Cheang MC; Yau C; Perou CM; Carey L; DeMichele A; Gray JW; Conway-Dorsey K; Lenburg ME; Buxton MB; Davis SE; van't Veer LJ; Hudis C; Chin K; Wolf D; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Livasy C; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; Au A; Hylton N;
Breast Cancer Res Treat; 2012 Apr; 132(3):1049-62. PubMed ID: 22198468
[TBL] [Abstract][Full Text] [Related]
10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
11. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
Candelaria RP; Bassett RL; Symmans WF; Ramineni M; Moulder SL; Kuerer HM; Thompson AM; Yang WT
Oncologist; 2017 Apr; 22(4):394-401. PubMed ID: 28314842
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
13. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Tripathy D; Wolverton DS; Rugo HS; Hwang ES; Ewing CA; Hylton NM
AJR Am J Roentgenol; 2005 Jun; 184(6):1774-81. PubMed ID: 15908529
[TBL] [Abstract][Full Text] [Related]
14. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
15. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
Jafri NF; Newitt DC; Kornak J; Esserman LJ; Joe BN; Hylton NM
J Magn Reson Imaging; 2014 Aug; 40(2):476-82. PubMed ID: 24347097
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
[TBL] [Abstract][Full Text] [Related]
17. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
[TBL] [Abstract][Full Text] [Related]
18. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
Li W; Arasu V; Newitt DC; Jones EF; Wilmes L; Gibbs J; Kornak J; Joe BN; Esserman LJ; Hylton NM;
Tomography; 2016 Dec; 2(4):378-387. PubMed ID: 28066808
[TBL] [Abstract][Full Text] [Related]
19. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
